Chen Yong, Wang Yong-Yong, Dai Lei, Chen Ming-Wu
Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
J Thorac Dis. 2023 Aug 31;15(8):4387-4395. doi: 10.21037/jtd-23-376. Epub 2023 Aug 11.
Esophagectomy is still advised as an additional treatment for patients with superficial esophageal cancer (EC, T1a-T1b) after endoscopic resection (ER). However, esophagectomy often deteriorates the general condition of EC patients. In recent years, adjuvant chemoradiotherapy (CRT) has been recognized as a reliable, non-surgical treatment that can improve the prognosis. How to combine ER with adjuvant therapy to bring maximal benefits to patients has become a hot clinical research hot topic. However, the current studies have mostly been conducted retrospectively, in single centers, and with small clinical samples; there have been few prospective and large sample size randomized controlled trials (RCTs). The aim of this systematic review and meta-analysis was to compare the outcomes of adjuvant CRT versus esophagectomy in the treatment of early EC, and to provide a reference for clinical research and practice.
A comprehensive and extensive literature search was performed via the databases of PubMed, Cochrane Library, Embase, and Web of Science online and all randomized cohort studies and retrospective cohort studies were collected. The quality of research was evaluated according to Cochrane's quality standards, and statistical analysis was conducted with Stata 13.0 and RevMan 5.3 software and followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA).
A total of 9 cohort studies, including 790 patients, were included for meta-analysis. The long term effects of the esophagectomy group were better than those of the CRT after ER group [odds ratio (OR) =6.08, 95% confidence interval (CI): 1.96 to 18.84, P=0.002] in disease-free survival (DFS) [hazard ratio (HR) =0.24, 95% CI: 0.07 to 0.85, P=0.03] and overall survival (OS) (HR =1.02, 95% CI: 0.57 to 1.82, P=0.94). Other survival indicators showed no significant difference (P>0.05).
The 2 groups showed no significant results in OS. Although we found that CRT may be suitable for patients with high-risk of relapse or unable to tolerate surgery, it cannot totally replace surgical treatment; further randomized trials are required to verify this view.
对于内镜切除术后的早期食管癌(EC,T1a-T1b)患者,食管切除术仍被建议作为一种额外的治疗方法。然而,食管切除术常常会使EC患者的一般状况恶化。近年来,辅助放化疗(CRT)已被公认为一种可靠的非手术治疗方法,可改善预后。如何将内镜切除与辅助治疗相结合,为患者带来最大益处已成为临床研究的热点话题。然而,目前的研究大多为回顾性、单中心且临床样本量较小;前瞻性且大样本量的随机对照试验(RCT)较少。本系统评价和荟萃分析的目的是比较辅助CRT与食管切除术治疗早期EC的疗效,为临床研究和实践提供参考。
通过PubMed、Cochrane图书馆、Embase和Web of Science在线数据库进行全面广泛的文献检索,收集所有随机队列研究和回顾性队列研究。根据Cochrane质量标准评估研究质量,使用Stata 13.0和RevMan 5.3软件进行统计分析,并遵循系统评价和荟萃分析的首选报告项目(PRISMA)。
共纳入9项队列研究,包括790例患者进行荟萃分析。在无病生存期(DFS)[风险比(HR)=0.24,95%置信区间(CI):0.07至0.85,P=0.03]和总生存期(OS)(HR =1.02,95%CI:0.57至1.82,P=0.94)方面,食管切除组的长期疗效优于内镜切除术后CRT组[优势比(OR)=6.08,95%CI:1.96至18.84,P=0.002]。其他生存指标无显著差异(P>0.05)。
两组在总生存期方面无显著差异。虽然我们发现CRT可能适用于复发风险高或无法耐受手术的患者,但它不能完全替代手术治疗;需要进一步的随机试验来验证这一观点。